Biotech receives award from DOD; Regulators accept Appili Therapeutics' NDA
EuMentis Therapeutics, a Boston-based biotech, has been handed an award from the US Department of Defense.
The $3 million award will be used by EuMentis to work on a small molecule for traumatic brain injury that aims to target the N-methyl-D-aspartate receptor. Specifically, the biotech will study three antagonists to evaluate TBI in an animal study this year. That study will be done in collaboration with a professor at the University of Pennsylvania.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.